TEAD4-siRNA as an Emerging Drug for the Treatment of Gastric Cancer

Yuxi Chen

doi:10.23977/tranc.2025.060113

TEAD4-siRNA as an Emerging Drug for the Treatment of Gastric Cancer

Download as PDF

DOI: 10.23977/tranc.2025.060113 | Downloads: 4 | Views: 70

Author(s)

Yuxi Chen ¹

Affiliation(s)

¹ Wuhan Number Six High School, Wuhan, Hubei, 430016, China

Corresponding Author

Yuxi Chen

ABSTRACT

As a downstream element that functions as an effector within the Hippo signaling pathway, TEAD4 has been linked to the proliferation, metastasis, and chemoresistance of gastric cancer. Silencing TEAD4 expression may provide a promising treatment approach. This study investigated the effects of TEAD4-targeting siRNA (TEAD4-siRNA) on AGS gastric cancer cells, focusing on cell proliferation, migration, invasion. A siRNA sequence targeting TEAD4 was designed and cloned into a SiRNA vector. AGS cells were transfected with the recombinant plasmid, and functional assays encompassing CCK-8 proliferation, transwell migration/invasion, wound healing, and ROS detection were performed. TEAD4 silencing by siRNA significantly inhibited AGS cell proliferation, migration, and invasion, while reducing colony formation capacity. Our TEAD4-siRNA effectively suppresses malignant phenotypes of gastric cancer cells and represents a potential therapeutic approach for gastric cancer treatment.

KEYWORDS

TEAD4; siRNA; Gastric Cancer; Hippo Pathway; Cell Proliferation; Migration; Gene Therapy

CITE THIS PAPER

Yuxi Chen, TEAD4-siRNA as an Emerging Drug for the Treatment of Gastric Cancer. Transactions on Cancer (2025) Vol. 6: 101-108. DOI: http://dx.doi.org/10.23977/tranc.2025.060113.

REFERENCES

[1] Sun B, Chen H, Gao X. Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application[J]. Journal of Controlled Release, 2021, 337: 698-717.
[2] Meliț L E, Mărginean C O, Borka Balas R. The most recent insights into the roots of gastric cancer[J]. Life, 2024, 14(1): 95.
[3] Harvey K F, Zhang X, Thomas D M. The Hippo pathway and human cancer[J]. Nature Reviews Cancer, 2013, 13(4): 246-257.
[4] Zhu Z, Ding R, Yu W, et al. YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer[J]. Cell Death & Differentiation, 2025, 32(5): 911-925.
[5] Janse van Rensburg H J, Azad T, Ling M, et al. The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1[J]. Cancer research, 2018, 78(6): 1457-1470.
[6] Qin S, Yan J, Xin J. Impact of Sirna-Mediated Tissue Inhibitor of Metalloproteinases-1 Knockdown on Proliferation and Apoptosis in Triple-Negative Breast Cancer: Bioinformatics and Experimental Insights[J]. Journal of Physiology & Pharmacology, 2025, 76(3).
[7] Fang T, Li L, Tariq Muhseen Z, et al. Strategic Timing of Gene Silencing: Cellular Kinetics‐Based Administration of siRNA for Optimized Photothermal Cancer Treatment[J]. Advanced Science, 2025: e10802.
[8] Bhat I P, Rather T B, Bhat G A, et al. TEAD4 nuclear localization and regulation by miR-4269 and miR-1343-3p in colorectal carcinoma[J]. Pathology-Research and Practice, 2022, 231: 153791.
[9] Jiao S, Li C, Hao Q, et al. VGLL4 targets a TCF4–TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer[J]. Nature communications, 2017, 8(1): 14058.
[10] Song J, Dang X, Shen X, et al. The YAP–TEAD4 complex promotes tumor lymphangiogenesis by transcriptionally upregulating CCBE1 in colorectal cancer[J]. Journal of Biological Chemistry, 2023, 299(4): 103012.
[11] Tang J Y, Yu C Y, Bao Y J, et al. TEAD4 promotes colorectal tumorigenesis via transcriptionally targeting YAP1[J]. Cell Cycle, 2018, 17(1): 102-109.
[12] Wang J, Wu X. TEAD4 transcriptionally activates TRIB3 to induce ferroptosis resistance through the MEK/ERK signaling pathway in colorectal Cancer[J]. Gut and Liver, 2025, 19(4): 579.
[13] Ye C, Wang W, Xia G, et al. A novel curcumin derivative cl-6 exerts antitumor effect in human gastric cancer cells by inducing apoptosis through hippo–YaP signaling pathway[J]. OncoTargets and therapy, 2019: 2259-2269.
[14] Yu T, Song J, Zhou H, et al. Nuclear TEAD4 with SIX1 overexpression is an independent prognostic marker in the stage I–III colorectal cancer[J]. Cancer Management and Research, 2021: 1581-1589.
[15] Maurizi A, Patrizii P, Teti A, et al. Novel hybrid silicon-lipid nanoparticles deliver a siRNA to cure autosomal dominant osteopetrosis in mice. Implications for gene therapy in humans[J]. Molecular Therapy Nucleic Acids, 2023, 33: 925-937.
[16] Saffie-Siebert S, Alam I, Sutera F M, et al. Effect of allele-specific Clcn7 G213R siRNA delivered via a novel nanocarrier on bone phenotypes in ADO2 mice on 129S background[J]. Calcified Tissue International, 2024, 115(1): 85-96.
[17] Verma P, Arora A, Rana K, et al. Gemini lipid nanoparticle (GLNP)-mediated oral delivery of TNF-α siRNA mitigates gut inflammation via inhibiting the differentiation of CD4+ T cells[J]. Nanoscale, 2022, 14(39): 14717-14731.
[18] Guo Y, Lee H, Fang Z, et al. Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles[J]. Science advances, 2021, 7(18): eabf7390.
[19] He S, Fan W, Wu N, et al. Lipid-based liquid crystalline nanoparticles facilitate cytosolic delivery of siRNA via structural transformation[J]. Nano letters, 2018, 18(4): 2411-2419.

Subscription

E-Mail Alert

Downloads:	1213
Visits:	93833

TEAD4-siRNA as an Emerging Drug for the Treatment of Gastric Cancer

Author(s)

Affiliation(s)

Corresponding Author

ABSTRACT

KEYWORDS

CITE THIS PAPER

REFERENCES

RESOURCES

JOIN US

PUBLICATION SERVICES

CONTACT US